14P Flat-dose Nivolumab (NIVO) As Second-Line (2L) Treatment (tx) in Asian Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): CheckMate 870 Long-Term Results

Su Lu,Ying Cheng,Jiangtao Zhou,M. Wang,Jun Zhao,B. Wang,G. Chen,Jing Feng,Zhe Ma,Lei Wu,C. Wang,Kening Ma,Siju Zhang,Ji Liang,Yuxian Song,Junxiang Wang,Yi‐Long Wu,A. Li,Y. Huang,Jian Chang

DOI: https://doi.org/10.1016/j.annonc.2022.02.023

IF: 51.769

2022-01-01

Annals of Oncology

Abstract:NIVO is approved in China as 2L tx for advanced NSCLC via weight-based 60-minute (min) infusion. We further investigated the safety and efficacy of the more convenient flat dosing via a 30-min infusion in pts with advanced NSCLC, including those with hepatis B virus (HBV) due to its prevalence in China. Asian (mostly Chinese) pts with previously treated advanced NSCLC received NIVO 240 mg over 30 min every 2 weeks (Q2W) for up to 2 years (y). High-grade (G3–5) select tx-related adverse events (sTRAE) were analysed by HBV infection status (primary endpoint). Secondary and exploratory endpoints included efficacy and patient-reported outcomes (PROs) among pt subgroups. Overall, 400 pts were treated: 383 non-HBV infected; 34 EGFR positive (+); 168 and 174 had PD-L1 ≥1% and <1%, respectively. Median (med) age was 61 y. Most pts were male (78.5%), had non-squamous histology (65.8%), and stage IV (77.3%) disease. Minimum follow-up (f/u) was 35.4 months (mo) and med tx duration was 3.24 mo. At a med f/u of 37.6 mo, occurrence of G3–4 sTRAE was low regardless of HBV status. No G5 sTRAEs were reported. Med overall survival was 14.2 (12.3–18.1) and 22.3 (10.0–NA) mo for non-HBV and HBV-infected, 19.3 (11.2–31.7) and 13.7 (11.5–18.1) mo for EGFR+ and negative, and 19.3 (12.9–23.5) and 13.3 (10.9–17.7) mo for PD-L1 ≥1% and <1% subgroups. No notable changes from baseline were observed in PROs among those subgroups.Table: 14PNon-HBVN=383HBVN=17G3−4 sTRAEs, n (%)Endocrine3 (0.8)1 (5.9)Gastrointestinal2 (0.5)0Hepatic8 (2.1)0Pulmonary5 (1.3)0Renal2 (0.5)0Skin7 (1.8)1 (5.9)Hypersensitivity00EfficacymOS, mo (95% CI)14.16 (12.25−18.07)22.31 (10.02−NA)2-year OS rate, % (95% CI)34 (29−39)44 (19−67)mPFS, mo (95% CI)3.61 (2.33−3.75)2.04 (1.64−10.22)2-year PFS rate, % (95% CI)10 (07−13)10 (01−34)ORR, % (95% CI)14.88 (11.47−18.85)17.65 (3.80−43.43)DOR, mo (95% CI)19.38 (11.04−24.97)NA (8.15−NA) Open table in a new tab NIVO 240 mg 30-min infusion Q2W was well-tolerated in Asian pts with previously treated advanced NSCLC, regardless of HBV, EGFR and PD-L1 status. Results were consistent with CheckMate 078 study. Data should be interpreted with caution given the small subgroup sample size.